MDRNA makes appointments to scientific advisory board
This article was originally published in Scrip
MDRNA, a biotechnology company developing and commercialising therapeutic products based on RNAi, has appointed Dr Beverly Davidson and Dr Carl Novina to its scientific advisory board. Dr Davidson is professor of medicine, neurology and physiology and biophysics in the department of internal medicine at the University of Iowa, while Dr Novina is an assistant professor in the department of pathology at Harvard Medical School, an assistant professor of cancer immunology/AIDS at Dana-Farber Cancer Institute and an associate member at the Broad Institute.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.